Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ETR029
- Development stage
- Phase 1
- Lead developer
- Elysium Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ETR029 is an orally administered hydrocodone prodrug being developed by Elysium Therapeutics for the treatment of acute moderate to severe pain. It is part of Elysium's O2P (Oral Overdose Protected) hydrocodone prodrug platform designed to reduce the risk of overdose by limiting how much of the active drug the body can absorb. ETR029 functions as an opioid receptor agonist.
- Brand names
- O2P hydrocodoneO-2P hydrocodoneO 2P hydrocodone
- Other names
- O2P hydrocodoneO-2P hydrocodoneO 2P hydrocodone
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on ETR029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ETR029.